1. Home
  2. PNR vs CYTK Comparison

PNR vs CYTK Comparison

Compare PNR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$75.07

Market Cap

13.0B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$78.27

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
CYTK
Founded
1966
1997
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.0B
10.4B
IPO Year
2003
2004

Fundamental Metrics

Financial Performance
Metric
PNR
CYTK
Price
$75.07
$78.27
Analyst Decision
Buy
Strong Buy
Analyst Count
16
19
Target Price
$109.73
$89.26
AVG Volume (30 Days)
1.9M
1.7M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
1.34%
N/A
EPS Growth
5.88
N/A
EPS
1.05
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$4.24
$7.37
Revenue Next Year
$4.82
$310.19
P/E Ratio
$71.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.93
$31.99
52 Week High
$113.95
$80.20

Technical Indicators

Market Signals
Indicator
PNR
CYTK
Relative Strength Index (RSI) 48.67 63.90
Support Level $70.35 $59.07
Resistance Level $75.66 $79.66
Average True Range (ATR) 1.70 3.20
MACD 0.69 0.56
Stochastic Oscillator 66.02 89.87

Price Performance

Historical Comparison
PNR
CYTK

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: